Stavudine extended release (once-daily, Bristol-Myers Squibb) for the treatment of HIV/AIDS

Abstract:

Introduction: Stavudine extended release (d4T XR) was a formulation which tried to solve the two main problems associated with the use of stavudine immediate release (d4T IR). These were twice daily dosing schema at a time when most formulations were long-life allowing once daily dosing; and that the use of d4T IR was associated with long-term toxicity through mitochondrial toxicity clinically expressed as peripheral neuropathy, pancreatitis and above all, lipodystrophy. The link between stavudine exposure and lipodystrophy had a great negative impact on its use in clinical practice. Areas covered: The authors cover the most relevant papers related to the efficacy and safety of d4T XR-based antiretroviral therapy. Expert opinion: The development of d4T XR has only been partially successful with regard to its objectives. Improved pharmacokinetic properties allow its once daily dosing, and although it exhibits …

Año de publicación:

2013

Keywords:

Fuente:

google